FIELD: medicine.
SUBSTANCE: invention methods relate to identification, selection, enrichment, depletion of populations of relaxing Tr1 cells and/or activated Tr1 cells, as well as in vitro monitoring of the therapy effect. The pharmaceutical compositions of the invention contain cells expressing CD4, CD25, CD127 and CD62L markers. The kit of the invention comprises means to determine CD4, CD25, CD127 and CD62L markers expression on the cell surface. The use of the invention allows to identify the relaxing Tr1 cells as having a CD4+CD25-CD127lo/-CD62Llo/- phenotype, and the activated Tr1 cells as having CD4+CD25+CD127lo/-CD62Llo/- phenotype.
EFFECT: ability to use to isolate, enrich or deplete the population of relaxing Tr1 cells or activated Tr1 cells.
15 cl, 2 tbl, 5 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF OBTAINING POPULATION OF HUMAN CD4+CD25+Foxp3+ T-LYMPHOCYTES ex vivo, DISEASE TREATMENT METHOD | 2008 |
|
RU2391401C2 |
METHOD OF HUMAN REGULATORY CD4CD25FOXP3T-CELL ENRICHMENT ex vivo | 2010 |
|
RU2437933C1 |
NEW SUBPOPULATION OF TREG CD8CD45RC CELLS AND ITS APPLICATIONS | 2016 |
|
RU2766691C2 |
METHOD FOR OBTAINING AUTOLOGOUS REGULATORY T-LYMPHOCYTES BY EX VIVO CULTIVATION IN PRESENCE OF HUMAN CHORIONIC GONADOTROPIN | 2022 |
|
RU2791738C1 |
ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
METHODS OF ISOLATING, CULTURING AND GENETIC ENGINEERING CELL POPULATIONS OF THE IMMUNE SYSTEM FOR ADOPTIVE THERAPY | 2015 |
|
RU2763795C2 |
METHODS AND COMPOSITIONS FOR OBTAINING GENETICALLY ENGINEERED CELLS | 2018 |
|
RU2795454C2 |
SYSTEM AND METHOD OF OBTAINING AND STORAGE OF ACTIVATED MATURE DENDRITIC CELLS | 2011 |
|
RU2575978C2 |
Authors
Dates
2017-08-08—Published
2011-04-15—Filed